Using Indication to Identify Product Launch Analogues
A New Enhancement to IQVIA’s Analogue Planner
For over 20 years, IQVIA Analogue Planner New Product (APNP) has supported clients in new product forecasting by simplifying the process of analogue selection. As all novel launches call for a long-term investment, it is important to have the right expectations for launch.
The key to quantifying the opportunity is identifying and applying the appropriate analogues to the analysis. This is where APNP plays a very important role. It provides a rich pool of historical product launches serving as potential benchmarks for analogue analysis, permitting the following use cases:
- Match a pipeline drug to existing products with similar characteristics
- Benchmark new product launch projections
- Compare dynamics of the drugs already in market
- Identify drivers for success or failure of new product launches.
The launches captured in APNP are categorized against 24 key product and environmental criteria that may affect launch success. The table below lists the various launch criteria available in APNP:
I want to know more about IQVIA Analogue Planner
Disease Enhancement
In an endeavor to continuously improve the APNP service, an enhancement was released in September 2021. Historically, products could only be categorized and selected for analysis based on their therapeutic class (ATC3 or ATC4). With this enhancement, two new criteria have been added to help clients in selecting products based on indications – Primary Indication and Major Indications - defined as follows:
Primary Indication: This tag is attributed to the indication accounting for the maximum market share of a product based on the sales by indication data from IQVIA Analytics Link.
Major Indications: This tag is given to all indications that sum up to 90% market share for a particular product but have an individual market share >=5% for the product in the country of interest, based on the sales by disease data from IQVIA Analytics Link.
Coverage
APNP has a coverage of over 9500 historical analogues and more than 85% of these analogues are tagged to diseases in the current module. The below exhibit is an illustration of the percentage of products that have been tagged with primary and major indications across 9 countries of APNP in this release.
Conclusion
The use and importance of different criteria within APNP will depend on the individual user and the type of analogue search required. But the addition of disease (Primary and Major indications) to the selection criteria should broaden the search options available to users and enable more robust analysis in the future.
Want to know more about how Analogue Planner can help answer your business needs?
Fill in the form and we’ll come back to you.
Copyright © 2025 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement
